RCM
GYRE icon

Rotella Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Rotella Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-20
Closed -$41K – 541
2014
Q4 		$41K Buy
+20
New +$38.5K 0.04% 312

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Rotella Capital Management's GYRE Position: Q1 2015 in Review

Rotella Capital Management sold out of Gyre Therapeutics (GYRE) in Q1 2015, closing a stake of 20 shares — an estimated $41K sold.

Rotella Capital Management first reported a position in GYRE in Q4 2014 and held it in 1 quarter. The position peaked at $41K in Q4 2014. 49 funds tracked by Wall St. Rank hold GYRE as of Q1 2015.

  • Rotella Capital Management reported no remaining Gyre Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Rotella Capital Management sold 20 Gyre Therapeutics shares in Q1 2015, an estimated $41K.
  • Rotella Capital Management first reported a position in Gyre Therapeutics in Q4 2014 and held it in 1 quarter.
  • Rotella Capital Management's Gyre Therapeutics position peaked at $41K in Q4 2014.
  • 49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2015.

Based on Rotella Capital Management's 13F filing for Q1 2015, filed 4 May 2015.